Patent ID: 9089549
Filing Date: 2015-07-28
Classification: A61K,A61L,A61P

Abstract:
1. A method of treating post-operative atrial fibrillation in a subject, comprising: providing an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said ECM composition further comprising a statin and an anti-inflammatory agent selected from the group consisting of (RS)-2-(4-(2-methylpropyl)phenyl) propanoic acid (Ibuprofen™), (8S,9S,10S,11S,13S,14S,16R,17S)-9-Fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one (Desoximetasone™), 1α-Methyl-17β-hydroxy-5α-androstan-3-one (Mesterolone™), (8S,9S,10S,13S,14S,1 7S)-17-Hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (Methandrostenolone™) and 5-Methyl-1-phenylpyridin-2-one (Pirfenidone™), said statin and anti-inflammatory agent being linked to said ECM, wherein, when said ECM composition is administered to damaged myocardium tissue of said subject, said statin and anti-inflammatory agent interact with said ECM and modulate inflammation of said myocardium tissue and induce myofibroblast proliferation and angiogenesis, whereby said ECM composition modulates electrical activity in the heart of said subject; and delivering a therapeutically effective amount of said ECM composition directly to post-operative damaged myocardium tissue of said subject, wherein said ECM composition modulates inflammation of said post-operative damaged myocardium tissue and induces said myofibroblast proliferation and angiogenesis and, thereby, bioremodeling and regeneration of new myocardium tissue, whereby said ECM composition reduces incidence of post-operative atrial fibrillation of said subject.